Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

Risultato della ricerca: Articlepeer review

Abstract

Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting.
Lingua originaleEnglish
pagine (da-a)1-10
Numero di pagine10
RivistaBreast Cancer Research and Treatment
Stato di pubblicazionePublished - 2021

Fingerprint

Entra nei temi di ricerca di 'Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study'. Insieme formano una fingerprint unica.

Cita questo